Big Pharma Stalwart vs. Risky Upstart: Evaluating Eli Lilly and Viking Therapeutics' Growth Potential
-
Eli Lilly is a large, established pharma company with an impressive track record and pipeline. Its diabetes and obesity drug tirzepatide could become the best-selling drug ever.
-
Viking Therapeutics is a small, clinical-stage biotech with an early-stage pipeline but huge growth potential if drugs like VK2735 and VK2809 succeed. Its shares recently doubled on positive trial data.
-
Eli Lilly generates billions in revenue and profits, pays a dividend, and expects fast EPS growth. But its upside is limited compared to a successful biotech.
-
Viking has no revenue or profits yet and carries substantial downside risk if its drugs fail or face regulatory issues. But its upside is enormous if successful.
-
Eli Lilly is the safer, more conservative option while Viking carries higher risk but more potential reward for aggressive investors.